메뉴 건너뛰기




Volumn 18, Issue 4, 2008, Pages 256-258

Neoadjuvant therapy for renal cancer;Traitement néoadjuvant du cancer du rein

Author keywords

Antiangiogenic; Metastatic renal cancer; Neoadjuvant therapy; Sunitinib

Indexed keywords

ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SUNITINIB;

EID: 43849100292     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2008.01.002     Document Type: Article
Times cited : (9)

References (6)
  • 1
    • 14644415949 scopus 로고    scopus 로고
    • Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    • Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23 (2005) 1028-1043
    • (2005) J Clin Oncol , vol.23 , pp. 1028-1043
    • Rini, B.I.1    Small, E.J.2
  • 2
    • 33646203800 scopus 로고    scopus 로고
    • Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein
    • Fergelot P., Rioux-Leclercq N., and Patard J.J. Voies moléculaires de l'angiogenèse tumorale et nouvelles approches thérapeutiques ciblées dans le cancer du rein. Prog Urol 15 (2005) 1021
    • (2005) Prog Urol , vol.15 , pp. 1021
    • Fergelot, P.1    Rioux-Leclercq, N.2    Patard, J.J.3
  • 3
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
    • (2006) J Clin Oncol , vol.24 , Issue.1 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 4
    • 33748590610 scopus 로고    scopus 로고
    • Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)
    • Motzer R.J., Hutson T.E., Tomczak P., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol (2006)
    • (2006) J Clin Oncol
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 5
    • 33646684668 scopus 로고    scopus 로고
    • Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC)
    • (abstract no. 3003)
    • Rixe O., Meric J.B., Bloch J., et al. Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). J Clin Oncol 23 (2005) 16S (abstract no. 3003)
    • (2005) J Clin Oncol , vol.23
    • Rixe, O.1    Meric, J.B.2    Bloch, J.3
  • 6
    • 33748117805 scopus 로고    scopus 로고
    • Cytoreductive nephrectomy in metastatic renal cell carcinoma
    • Healy K.A., Marshall F.F., and Ogan K. Cytoreductive nephrectomy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 6 (2006) 1295-1304
    • (2006) Expert Rev Anticancer Ther , vol.6 , pp. 1295-1304
    • Healy, K.A.1    Marshall, F.F.2    Ogan, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.